SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. __)
Longboard Pharmaceuticals, Inc. | ||
(Name of Issuer) | ||
Common Stock, par value $0.0001 per share | ||
(Title of Class of Securities) | ||
54300N103 | ||
(CUSIP Number) | ||
December 31, 2021 | ||
(Date of Event Which Requires Filing of this Statement) | ||
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
|_| Rule 13d-1(b)
|_| Rule 13d-1(c)
|X| Rule 13d-1(d)
CUSIP No. | 54300N103 | SCHEDULE 13G | Page | 2 | of | 4 | ||||||||||||||
1 | Name Of Reporting Persons | |||||||
Arena Pharmaceuticals, Inc. | ||||||||
2 | Check The Appropriate Box If A Member Of A Group (See Instructions) | (a) |_| | ||||||
(b) |_| | ||||||||
3 | SEC Use Only | |||||||
4 | Citizenship Or Place Of Organization | |||||||
Delaware | ||||||||
Number of Shares Beneficially Owned By Each Reporting Person With | 5 | Sole Voting Power | ||||||
3,978,540 | ||||||||
6 | Shared Voting Power | |||||||
0 | ||||||||
7 | Sole Dispositive Power | |||||||
3,978,540 | ||||||||
8 | Shared Dispositive Power | |||||||
0 | ||||||||
9 | Aggregate Amount Beneficially Owned By Each Reporting Person | ||||
3,978,540 | |||||
10 | Check If The Aggregate Amount In Row (9) Excludes Certain Shares | ||||
|_| | |||||
11 | Percent Of Class Represented By Amount In Row 9 | ||||
23.1%1 | |||||
12 | Type Of Reporting Person (See Instructions) | ||||
CO | |||||
1 The percentage is calculated based on 17,215,350 shares of Common Stock outstanding as of November 5, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 4, 2021.
CUSIP No. | 54300N103 | SCHEDULE 13G | Page | 3 | of | 4 | ||||||||||||||
Item 1 | (a). | Name of Issuer: Longboard Pharmaceuticals, Inc. | |||||||||
Item 1 | (b). | Address of Issuer's Principal Executive Offices: 4275 Executive Square, Suite 950, La Jolla, California 92037 | |||||||||
Item 2 | (a). | Name of Person Filing: Arena Pharmaceuticals, Inc. | |||||||||
Item 2 | (b). | Address of Principal Business Office: 136 Heber Avenue, Suite 204, Park City, Utah 84060 | |||||||||
Item 2 | (c). | Citizenship: Delaware | |||||||||
Item 2 | (d). | Title of Class of Securities: Common Stock, par value $0.0001 per share (“Common Stock”) | |||||||||
Item 2 | (e). | CUSIP Number: 54300N103 | |||||||||
Item 3. | Not Applicable | ||||||||||
Item 4. | Ownership. | ||||||||||
(a) | Amount beneficially owned: 3,978,540 | ||||||||||
(b) | Percent of Class: 23.1% | ||||||||||
(c) | Number of shares as to which such person has: | ||||||||||
(i) | Sole power to vote or to direct the vote: 3,978,540 | ||||||||||
(ii) | Shared power to vote or to direct the vote: 0 | ||||||||||
(iii) | Sole power to dispose or to direct the disposition of: 3,978,540 | ||||||||||
(iv) | Shared power to dispose or to direct the disposition of: 0 | ||||||||||
Item 5. | Ownership of Five Percent or Less of a Class: Not Applicable | ||||||||||
Item 6. | Ownership of More than Five Percent on Behalf of Another Person: Not Applicable | ||||||||||
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person: Not Applicable | ||||||||||
Item 8. | Identification and Classification of Members of the Group: Not Applicable | ||||||||||
CUSIP No. | 54300N103 | SCHEDULE 13G | Page | 4 | of | 4 | ||||||||||||||
Item 9. | Notice of Dissolution of Group: Not Applicable | ||||||||||
Item 10. | Certification: Not Applicable | ||||||||||
SIGNATURE
After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct.
Dated: March 10, 2022
ARENA PHARMACEUTICALS, INC. | ||
By: /s/ Amit D. Munshi | ||
Name: Amit D. Munshi | ||
Title: President and Chief Executive Officer | ||